Mineralys Therapeutics, Inc. Common Stock
MLYS
$31.12
+10.32%
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for cardiorenal conditions driven by dysregulated aldosterone. Its lead candidate, lorundrostat, is an orally administered aldosterone synthase inhibitor being developed for hypertension and related comorbidities like chronic kidney disease and obstructive sleep apnea. The current investor narrative is entirely driven by the clinical and regulatory progress of lorundrostat, with the stock's valuation reflecting binary speculation on the drug's potential approval and commercial success in a large, underserved market. Recent attention is likely centered on upcoming clinical trial readouts, regulatory milestones, and the company's ability to fund its development pipeline through to commercialization.…
MLYS
Mineralys Therapeutics, Inc. Common Stock
$31.12
Investment Opinion: Should I buy MLYS Today?
Rating: Hold. The core thesis is that MLYS is a high-risk, binary clinical-stage biotech where the current price reflects a balanced probability of success, but the severe technical breakdown and lack of near-term catalysts warrant caution despite a strong balance sheet. Supporting evidence includes: 1) A pristine balance sheet with $172.92M cash and zero debt, providing a multi-year runway. 2) Improving operational metrics, with loss per share narrowing from -$0.98 to -$0.40 YoY. 3) A speculative valuation with no traditional multiples (PS=0, PE=-15.88), making it purely a call option on lorundrostat. 4) The stock trades 31.6% above its 52-week low, offering a potential floor but also highlighting significant recent selling pressure with a -21.35% 1-month return. The thesis would upgrade to a Buy on positive Phase 3 data for lorundrostat or a sustained technical reversal above the $30 resistance level. It would downgrade to a Sell on a breakdown below the $12.59 support, a failed trial, or a dilutive financing announcement. Relative to its own history and the binary nature of its business, the stock is fairly valued, pricing in both the large potential upside and the high probability of further dilution or clinical failure.
Sign up to view all
MLYS 12-Month Price Forecast
MLYS is a classic binary biotech bet where the current price balances a strong balance sheet against poor technicals and no near-term catalysts. The improving loss per share is a positive, but it is overshadowed by the stock's breakdown from its highs and the high probability of future dilution. The stance is neutral due to the offsetting factors; the lack of a clear near-term catalyst suggests the stock may languish. We would upgrade to bullish on a confirmed technical reversal above $30 coupled with positive clinical news. We would downgrade to bearish on a break below $20 toward the $12.59 low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Mineralys Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $48.50 and implied upside of +55.9% versus the current price.
Average Target
$48.50
0 analysts
Implied Upside
+55.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$30 - $56
Analyst target range
Insufficient analyst coverage data is available to form a consensus price target or recommendation distribution. The provided data includes institutional rating actions but lacks the crucial average target price, target range, and number of analysts forming a consensus. This limited coverage is typical for a small to mid-cap, recently listed (2023) biotech firm and leads to higher volatility and less efficient price discovery, as the stock is more susceptible to moves based on sparse news and trading by specialized healthcare funds rather than broad institutional analysis. The available institutional ratings show a pattern of reiterated 'Buy' or 'Overweight' ratings from firms like B of A Securities, Stifel, HC Wainwright, and Wells Fargo throughout 2025 and into early 2026, with only Jefferies showing a 'Hold'. This suggests a generally bullish sentiment among the limited covering analysts, who are likely focused on the long-term potential of lorundrostat. The absence of a defined target range, however, makes it impossible to quantify the implied upside or the assumptions behind bullish or bearish cases, leaving investors to rely on the binary outcome of clinical trials.
Drowning in data?
Find the real signal!
Bulls vs Bears: MLYS Investment Factors
The bear case currently holds stronger evidence, driven by severe technical deterioration, the absence of revenue, and a high cash burn rate that necessitates future dilution. The bull case rests on a pristine balance sheet, improving operational efficiency, and the large potential of its lead drug candidate. The single most important tension in the investment debate is the binary outcome of lorundrostat's clinical development: positive data could trigger a dramatic re-rating, while a setback could send the stock toward its 52-week low of $12.59, representing nearly 50% downside from current levels.
Bullish
- Strong Cash Position & No Debt: The company holds $172.92 million in cash with zero debt, providing a significant runway to fund its pivotal clinical trials. With a current ratio of 43.76, the balance sheet is exceptionally clean, mitigating near-term bankruptcy risk and allowing focus on R&D.
- Improving Loss Per Share: The quarterly loss per share has improved sequentially from -$0.98 in Q4 2024 to -$0.40 in Q4 2025, a 59% reduction. This trend indicates more efficient capital usage and extends the cash runway, a critical metric for pre-revenue biotechs.
- Analyst Sentiment Leans Bullish: Available institutional ratings from firms like BofA, Stifel, and Wells Fargo have reiterated 'Buy' or 'Overweight' ratings throughout 2025 and early 2026. This suggests specialist healthcare analysts see long-term value in the lorundrostat pipeline despite recent price weakness.
- Addressing Large Market Opportunity: Lorundrostat targets hypertension and related cardiorenal conditions, a massive and underserved multi-billion dollar market. Success in this space could justify the current speculative valuation, as reflected in the analyst revenue estimate for a future period averaging $1.13 billion.
Bearish
- Severe Technical Downtrend: The stock is down 38.47% over six months and 21.35% in the last month, decisively breaking its uptrend. Trading at $23.69 places it near the bottom of its 52-week range ($12.59-$47.65), indicating strong negative momentum and sentiment.
- Pre-Revenue with No Near-Term Sales: The company has zero revenue and deeply negative free cash flow of -$142.43 million TTM. Valuation is purely speculative, based on binary clinical outcomes, making the stock highly sensitive to trial data and regulatory news.
- High Cash Burn & Dilution Risk: With a quarterly net loss of $32.23 million and negative ROE of -23.9%, the company is burning cash rapidly. Future equity raises are highly probable to fund operations, posing a significant dilution risk to current shareholders.
- Limited Analyst Coverage & Price Discovery: Insufficient consensus analyst target data exists, with only a handful of firms covering the stock. This lack of coverage leads to higher volatility and inefficient price discovery, making the stock prone to exaggerated moves on sparse news.
MLYS Technical Analysis
The stock is in a pronounced downtrend, having declined 38.47% over the past six months and 21.35% in the last month alone, significantly underperforming the broader market. With a current price of $23.69, MLYS is trading at approximately 31.6% of its 52-week range ($12.59 to $47.65), positioning it much closer to its yearly lows, which suggests either a deep value opportunity or a reflection of deteriorating fundamentals and negative sentiment. The 1-year price change of +51.66% is misleading as it captures a prior rally from a much lower base, while the recent trajectory has been decisively negative, indicating a major trend reversal. Recent momentum is severely bearish and accelerating, with the 1-month decline of -21.35% far outpacing the 3-month drop of -10.91%. This divergence from the longer-term positive 1-year trend signals a breakdown, likely driven by negative clinical or financial news not captured in the price data. The stock's beta of 0.565 indicates it has been less volatile than the market, but this low beta is typical for a biotech stock awaiting binary catalysts and does not preclude sharp, idiosyncratic moves based on company-specific events. Key technical support is clearly defined at the 52-week low of $12.59, while resistance sits at the recent trading range highs near $38 from December 2025. A breakdown below $12.59 would signal a complete loss of confidence and potentially trigger further selling, while a sustained move above the $30-$31 level (recent highs from May 2026) would be needed to suggest a reversal of the downtrend. The stock's low beta relative to the SPY suggests its price action is driven more by company-specific risk than market movements, which is typical for pre-revenue biotech firms.
Beta
0.68
0.68x market volatility
Max Drawdown
-52.5%
Largest decline past year
52-Week Range
$22-$48
Price range past year
Annual Return
-13.4%
Cumulative gain past year
| Period | MLYS Return | S&P 500 |
|---|---|---|
| 1m | +13.8% | -0.9% |
| 3m | +31.0% | +5.6% |
| 6m | +15.3% | +15.0% |
| 1y | -13.4% | +18.1% |
| ytd | -12.9% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MLYS Fundamental Analysis
As a pre-revenue clinical-stage biotech, Mineralys has no product sales, with revenue of $0 reported for the quarter ending December 31, 2025. The company's financials are entirely defined by its research and development burn rate, with no revenue growth trajectory to analyze until lorundrostat potentially gains regulatory approval. The investment case is purely a call on the clinical success and future commercial potential of its pipeline, making traditional revenue analysis inapplicable at this stage. The company is deeply unprofitable, reporting a net loss of $32.23 million and a gross profit of -$13,000 for Q4 2025. Margins are not meaningful as there are no sales; the gross loss is a nominal cost of revenue. The loss per share improved to -$0.40 in Q4 2025 from -$0.98 in Q4 2024, indicating a narrowing loss on a per-share basis, which is a positive trend driven by share count increases and potentially more efficient R&D spending. This trajectory toward reduced losses is critical for extending its cash runway. The balance sheet shows a strong liquidity position with a current ratio of 43.76 and cash of $172.92 million as of Q4 2025, providing a substantial runway to fund operations. The company has no debt, with a debt-to-equity ratio of 0, minimizing financial risk. However, free cash flow is deeply negative at -$142.43 million TTM, indicating the company is entirely dependent on equity financing to fund its R&D burn. The negative ROE of -23.9% and ROA of -21.3% reflect the asset-intensive, loss-making nature of drug development before commercialization.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-142431000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MLYS Overvalued?
Given the company's negative net income and EBITDA, the primary valuation metric is the Price-to-Sales (PS) ratio. However, with zero revenue, the PS ratio is 0, rendering traditional sales-based multiples meaningless. Therefore, valuation is entirely based on future potential, modeled through discounted cash flow analyses of the pipeline, which is not provided in the data. The forward PE of -11.3x is also negative and not a useful valuation tool for a pre-revenue company. Peer comparison using standard multiples is not feasible as the company lacks revenue, profits, or positive EBITDA. Valuation for a stock like MLYS is derived from net present value estimates of its drug pipeline, often benchmarked against similar-stage biotechs or acquisition premiums. The absence of standard positive valuation multiples (PE, PS, EV/EBITDA) highlights the speculative, binary nature of the investment, where the stock price is a proxy for the probability-adjusted value of lorundrostat. Historical context shows the stock's own trailing PE ratio has ranged from deeply negative values, recently at -15.88. The Price-to-Book ratio is currently 3.80, which is above some historical quarters (e.g., 2.47 in Q1 2025) but below others (4.52 in Q4 2025). Trading near the middle of its own historical PB range suggests the market is not pricing in extreme optimism or pessimism relative to its recent past, but the book value is largely cash, so this multiple reflects the premium placed on its intellectual property and clinical assets over its net cash position.
PE
-15.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-14.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on the company's complete lack of revenue and substantial cash burn. With a TTM free cash flow of -$142.43 million and a quarterly net loss of $32.23 million, MLYS is entirely dependent on its $172.92 million cash reserve. At the current burn rate, this provides a runway of approximately 5-6 quarters before requiring additional financing, which will almost certainly be dilutive given the negative earnings and lack of debt capacity. The investment is a pure bet on clinical success, with no underlying business to cushion failure. Market & Competitive Risks are pronounced due to the stock's speculative nature and recent poor performance. Trading at a Price-to-Book ratio of 3.80, the market is assigning a significant premium to its intellectual property over its net cash value. The stock's low beta of 0.565 is deceptive; while it indicates low correlation with the market, the stock exhibits high idiosyncratic volatility, as evidenced by its 51.66% maximum drawdown. The primary risk is valuation compression if clinical progress stalls or competing therapies gain traction, as the stock has no earnings or sales multiples to provide a valuation floor. Worst-Case Scenario involves a clinical failure or significant safety setback for lorundrostat. Given the single-asset nature of the company, such an event would render its pipeline worthless, leading to a rapid repricing toward its liquidation value (primarily cash). The realistic downside target is the 52-week low of $12.59, which represents a -47% decline from the current price of $23.69. A breach of this level could trigger further selling, potentially pushing the stock toward its cash-per-share value, resulting in total losses for equity holders if the company winds down.
FAQ
The key risks are: 1) Clinical Failure Risk: The entire investment thesis hinges on lorundrostat's success; negative trial data could erase most of the stock's value. 2) Financial/Dilution Risk: With a TTM free cash flow of -$142.43 million, the company will need to raise capital, likely through dilutive equity offerings. 3) Market & Sentiment Risk: The stock is in a severe downtrend (-21.35% in 1 month) and has limited analyst coverage, leading to volatile, sentiment-driven price action. 4) Competitive Risk: Other companies developing treatments for hypertension and cardiorenal diseases could surpass lorundrostat's efficacy or safety profile.
The 12-month forecast is highly bifurcated, with outcomes dependent on clinical data. The base case (50% probability) sees the stock trading between $20 and $30 as it digests news and faces dilution concerns. The bull case (25% probability) targets $38 to $47.65 (the 52-week high) on positive trial results. The bear case (25% probability) projects a decline to the $12.59 to $18 range on a clinical setback or dilutive financing. The base case is most likely, assuming no major binary news, but the stock's path will be dictated by company-specific catalysts rather than market movements.
MLYS cannot be valued using traditional metrics like P/E (currently -15.88) or P/S (0), as it has no revenue or earnings. Its valuation is entirely based on the net present value of its pipeline. The Price-to-Book ratio of 3.80 indicates the market is valuing its intellectual property at a premium over its net asset value (largely cash). Compared to its own 52-week range, trading at 31.6% from the low suggests it is not priced for extreme optimism. The stock is fairly valued relative to the high-risk, binary nature of its business, embedding both the large market opportunity and the significant risk of failure.
MLYS is a speculative buy only for investors comfortable with binary, high-risk clinical outcomes. The stock offers significant potential upside if lorundrostat succeeds, supported by a strong cash position of $172.92 million and zero debt. However, it is a poor buy for risk-averse investors, given its 38.5% six-month decline, lack of revenue, and high probability of future share dilution. It could be a good buy for a small, speculative portion of a portfolio if purchased on weakness near key support levels, with the understanding that a total loss is possible.
MLYS is unsuitable for short-term trading due to its low beta (0.565) and company-specific catalyst-driven nature, which makes timing entries and exits extremely difficult. It is only appropriate for long-term investors with a 3-5 year horizon who can wait for the clinical development and regulatory approval process to unfold. The stock pays no dividend and offers no income, and its value will be determined by multi-year clinical and commercial milestones. Given the high volatility and binary outcome, a minimum holding period should align with the next major clinical catalyst, but investors must be prepared to hold through significant price swings.
